A wearable that could eliminate that ritual would transform how those people manage their condition.
At the edge of medicine and miniaturization, a Japanese startup named Quantum Operation stepped forward at CES with a claim that has eluded Apple, MIT, and well-funded predecessors alike: a wristwatch that reads blood sugar without drawing blood. The promise is not new — it has consumed tens of millions of dollars and some of the brightest biomedical minds of the past decade — but the need it answers is ancient and urgent, felt daily by millions who must wound themselves simply to know how their bodies are faring. Whether this prototype marks a genuine breakthrough or another chapter in a long story of optimistic failure remains, for now, an open question that only rigorous science can close.
- A noninvasive blood glucose reading in twenty seconds from a wristwatch would end a painful daily ritual for millions of diabetes patients — the stakes could not be more personal.
- The graveyard of similar ambitions is well-populated: C8 MediSensors burned through sixty million dollars and still couldn't tame the variability that makes wrist-based glucose readings unreliable across different bodies.
- Apple has quietly chased this same holy grail for years, assembling secret biomedical teams and absorbing talent from failed predecessors, yet its flagship wearable still cannot do what Quantum Operation claims its prototype can.
- A virtual trade show offers no independent verification — the device exists, for now, as a demonstration in a theater of optimism, where polished promises routinely outpace working technology.
- The path to legitimacy runs through peer-reviewed studies, regulatory certification, and real-world use — none of which Quantum Operation has yet provided, and all of which previous contenders stumbled on.
At CES this January, Quantum Operation, a Japanese startup, unveiled a smartwatch prototype carrying a claim that has haunted the wearable industry for years: the ability to measure blood glucose without a single drop of blood. The device uses a miniature spectrometer embedded in both the watch body and its band, scanning the wrist for glucose biomarkers and returning a reading in twenty seconds. The company says proprietary spectroscopy materials are the key ingredient — though it has offered little else by way of technical transparency. Beyond glucose, the watch also tracks heart rate and performs electrocardiograms, and Quantum Operation envisions selling the hardware to insurers and healthcare providers while building a data platform around the information it collects.
The weight of this claim is best understood against the history of those who tried before. Apple has pursued noninvasive glucose monitoring as a kind of internal moonshot, recruiting biomedical engineers and even absorbing talent from C8 MediSensors — a startup that raised sixty million dollars from investors including GE before collapsing in 2013, defeated by the stubborn variability of readings across different bodies. Researchers at MIT and the University of Missouri have explored laser and fiber optic approaches with promising accuracy, but none have translated cleanly into something a person could simply wear.
Trade shows, especially virtual ones, are not laboratories. There is no way to independently test the device or pressure-check the claims. The real reckoning will come through peer-reviewed research, regulatory approval, and the lived experience of patients. But if Quantum Operation has genuinely solved what a decade of effort and hundreds of millions of dollars could not, the reward is immense — a world where millions of people no longer have to wound themselves daily just to understand their own bodies.
At CES this January, a Japanese startup named Quantum Operation showed off a smartwatch that looked, at first glance, like any number of Apple Watch imitators flooding the market. But the company made a specific claim about what it could do: measure blood sugar without drawing blood.
The prototype uses a miniature spectrometer built into the watch and its band. The idea is simple enough in theory. A person puts on the device, touches the screen to activate the glucose scan, and waits twenty seconds. The watch then displays the blood sugar reading directly on its face. The spectrometer works by scanning the blood in the wrist for biomarkers that reveal glucose levels. Quantum Operation says the secret lies in proprietary spectroscopy materials engineered into both the hardware and the band itself.
Beyond glucose monitoring, the device also measures heart rate and can perform electrocardiograms—capabilities the Apple Watch already offers. The company envisions selling the hardware to insurers and healthcare providers, then building a data platform to collect and analyze the vast amount of information that would flow from patients wearing the device. No release date or price has been announced.
What makes this claim significant is the long shadow of failure that precedes it. For years, Apple has pursued noninvasive blood sugar monitoring as a kind of holy grail. The company assembled a secret team of biomedical engineers dedicated to the problem, even recruiting former employees from C8 MediSensors, a startup that had tried and failed to crack the same challenge. C8 raised sixty million dollars from investors including GE, but couldn't overcome a fundamental problem: readings varied from person to person, and the company ran out of money before solving the variability issue. The company shut down in early 2013. Researchers at MIT and the University of Missouri have explored using lasers and fiber optic cables pressed against the wrist, achieving readings comparable to traditional finger-prick tests, but that approach doesn't translate easily into a wearable form factor.
Yet despite all this investment and effort, Apple Watch still cannot measure blood glucose noninvasively. The technology remains elusive.
Questioning whether Quantum Operation's device actually works is fair. Trade shows are theaters of optimism. Steve Jobs famously demoed an iPhone that barely functioned. A virtual CES, held online during the pandemic, makes validation even harder—there's no way to independently test the device or verify the claims. The real proof will come through peer-reviewed studies, medical device certifications from regulatory bodies, and actual users wearing the device in their daily lives.
But if Quantum Operation delivers on its promise, the implications are substantial. Millions of people with diabetes require daily blood sugar monitoring. Many prick their fingers multiple times a day, drawing blood to feed into a meter. A wearable that could eliminate that ritual—that could provide continuous, accurate readings without pain or hassle—would transform how those people manage their condition. The question now is whether this Japanese startup has finally solved what Apple, MIT, and others have struggled with for a decade.
Notable Quotes
Quantum Operation says it expects to sell its hardware to insurers and healthcare providers, as well as building a big data platform to collect and examine information generated by patients wearing the device.— Engadget reporting on Quantum Operation's business model
The Hearth Conversation Another angle on the story
Why does this matter so much? It's just a watch that measures blood sugar.
Because millions of people with diabetes do finger-prick tests multiple times a day. It hurts. It's inconvenient. It's a constant reminder of their condition. A truly noninvasive way to monitor glucose would change the texture of daily life for those people.
But companies have tried this before. Why should we believe Quantum Operation will succeed where others failed?
We shouldn't, not yet. C8 MediSensors had sixty million dollars and still couldn't solve the variability problem—the fact that readings differ from person to person. That's a real technical wall. What Quantum Operation claims is that their proprietary spectroscopy materials have cracked it. But that's a claim, not proof.
What would proof look like?
Peer-reviewed studies published in medical journals. Regulatory approval from bodies like the FDA. And most importantly, real people wearing the device for months and comparing the readings to traditional blood tests. That's where the truth emerges.
Apple has been working on this for years. Why haven't they solved it?
Because it's genuinely hard. You're trying to measure something inside the body through skin and tissue without breaking the skin. Apple assembled brilliant engineers, even hired people from the failed C8 team. But brilliant engineers can't always overcome physics. Sometimes the problem is just harder than the resources available.
So what happens next?
Quantum Operation will need to move from demo to clinical validation. If they can do that, if the readings hold up under scrutiny, then we're looking at a real shift in how diabetes is managed. If they can't, it joins the long list of promising health tech that didn't survive contact with reality.